08:00 AM EDT, 08/07/2024 (MT Newswires) -- Intra-Cellular Therapies ( ITCI ) reported a Q2 net loss Wednesday of $0.16 per diluted share, narrowing from a loss of $0.45 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.21.

Total revenue for the quarter ended June 30 was $161.4 million, compared with $110.8 million a year earlier.

Analysts surveyed by Capital IQ expected $157.9 million.

Price: 77.99, Change: -0.18, Percent Change: -0.23